• Palatin Technologies posted fiscal third-quarter net loss of USD 1.4 million, or USD 0.37 per share, narrowing from USD 4.8 million, or USD 9.13 per share, a year earlier.
• Revenue swung to USD 3.9 million from no revenue, while operating loss narrowed to USD 1.6 million from USD 4.8 million.
• Operating expenses rose to USD 5.5 million from USD 4.8 million, due to higher compensation costs and professional fees.
• Cash and cash equivalents totaled USD 10.2 million at March 31, with USD 2.2 million of other receivables expected during quarter ending June 30, 2026; funding runway projected through June 30, 2027.
• Once-weekly injectable MC4R selective peptide agonist remained on track for IND submission in fourth-quarter 2026, while a next-generation oral MC4R selective agonist candidate targeted IND submission in first-half 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palatin Technologies Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605130730PR_NEWS_USPR_____PH57945) on May 13, 2026, and is solely responsible for the information contained therein.